Gene expression of , , , and topoisomerase IIα as an indicator of chemotherapy response in AML treated with cytarabine and daunorubicin.

Clicks: 421
ID: 55090
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #8 of 31 articles by views in Cancer management and research

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Acute myeloid leukemia patients are commonly treated with cytarabine (Ara-C) and anthracyclines but the sustained remission rate is not very promising. We explored the role of drug-metabolizing enzymes and transporters in the therapeutic response.Bone marrow and peripheral blood samples of 90 newly diagnosed acute myeloid leukemia patients treated with standard 3+7 regimen were analyzed through real-time PCR for expression of human equilibrative nucleoside transporter 1, deoxycytidine kinase, cytidine deaminase (), deoxycytidine monophosphate deaminase () and topoisomerase IIα (). The expression of these markers was studied in relationship with good (persistent remission) and poor therapeutic response (relapse/resistance).High expression in peripheral blood was associated with good response (=0.006). Relapse was higher among low expressors of in peripheral blood (OR: 26.25). Bone marrow expression followed a similar trend but did not reach statistical significance. In contrast, patients with high bone marrow expression had poor response (OR: 3; =0.043). One-year disease-free survival (DFS) was better among those with high bone marrow (=0.04) or (=0.03) expression. High bone marrow expression also had better DFS at 6 months (=0.04) and at 12 months (=0.04).High expression of in peripheral blood is a favorable indicator of persistent remission, good therapeutic response and DFS. High and low expression in bone marrow is associated with poor therapeutic outcome.
Reference Key
kulsoom2018genecancer Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kulsoom, Bibi;Shamsi, Tahir Sultan;Afsar, Nasir Ali;
Journal Cancer management and research
Year 2018
DOI
10.2147/CMAR.S181299
URL
Keywords
aml survival cda anthracyclines antimetabolites dck dcmpd hent1 topoisomerase iiα

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.